

# The Florida Cancer Data System's Memo

January 2024

## ICD-O-3 Implementation Guidelines

The ICD-O-3 Implementation Guidelines for cases diagnosed on or after January 1, 2024 are posted on the NACCR Website <https://www.naacr.org/icdo3/> and on the FCDS website under What is New. The majority of changes for 2024 are new related terms for existing codes, five new ICD-O codes, four reportable and one non-reportable, and one histology that has changed behavior and is now reportable. Please be sure to read the implementation guidelines before reviewing the tables below for more specific instructions.

### TABLE 1: 2024 ICD-O-3.2 UPDATE (NUMERICAL ORDER)

Table 1 lists all changes for 2024 including five new ICD-O codes and terms, one code with changes to behavior, and new preferred or related terms, in numerical order by ICD-O number.

### TABLE 2: 2024 ICD-O-3.2 UPDATE (ALPHABETIC ORDER)

Table 2 lists all changes for 2024 including five new ICD-O codes and terms, one code with changes to behavior, and new preferred or related terms, in alpha order by histology term.

#### WHAT'S NEW:

*The following information is currently available on the FCDS website.*

FCDS RESEARCH  
JOURNAL PUBLICATIONS  
REPORT

FCDS/NAACCR  
EDITs Metafile  
V23B Metafile,  
posted on 11/28/2023

**FCDS** Florida Cancer Data System

Florida Statewide Cancer  
Registry

(Continued on page 2)



# Florida Cancer Data System Deadlines, Updates, & Reminders

(Continued from page 1)

**Table 1: 2024 ICD-O-3.2 Update (Numerical)**

- Codes/terms listed numerically
- Only new terminology to existing ICD-O-3.2 codes are included in the 2024 ICD-O Implementation guidelines and documentation. Terms are those listed in WHO Blue Books
- Update based on 5<sup>th</sup> Ed Classification of Urinary and Male Genital Tumors

ICD-O Code	Term	Required SEER	Required NPCR	Required CoC	Required CCCR	Remarks
8020/3	Poorly differentiated urothelial carcinoma	Y	Y	Y	Y	Related term
8070/3	Pure squamous carcinoma of urothelial tract	Y	Y	Y	Y	New term
8085/3	Squamous cell carcinoma, HPV-associated	Y	Y	Y	Y	Valid for C60.; C63.2 beginning 1/1/2024 p16 is a valid test to determine HPV status and can be used to code HPV associated and HPV independent histologies
8086/3	Squamous cell carcinoma, HPV-independent	Y	Y	Y	Y	Valid for C60.; C63.2 beginning 1/1/2024 p16 is a valid test to determine HPV status and can be used to code HPV associated and HPV independent histologies
8120/3	Conventional urothelial carcinoma	Y	Y	Y	Y	New term
	Large nested urothelial carcinoma	Y	Y	Y	Y	New term
	Tubular and microcystic urothelial carcinoma					New term
8122/3	Plasmacytoid urothelial carcinoma	Y	Y	Y	Y	Related term
8130/2	Non-invasive papillary urothelial carcinoma, low-grade	Y	Y	Y	Y	New term
	Low-grade papillary urothelial carcinoma with an inverted growth pattern	Y	Y	Y	Y	New term
	Non-invasive papillary urothelial carcinoma, high-grade	Y	Y	Y	Y	New term

(Continued on page 3)



# Florida Cancer Data System Deadlines, Updates, & Reminders

(Continued from page 2)

	Non-invasive high-grade papillary urothelial carcinoma with an inverted growth pattern	Y	Y	Y	Y	New term
8140/3	Prostatic intraepithelial-like carcinoma (C61.9)	Y	Y	Y	Y	Related term
8147/3	Adenoid cystic (basal cell) carcinoma (C61.9)	Y	Y	Y	Y	Related term
8260/0	Tubulopapillary adenoma	N	N	N	N	New term. Not reportable
8311/3	Eosinophilic solid and cystic RCC (C64.9)	Y	Y	Y	Y	New term
	TFE3-rearranged RCC (C64.9)	Y	Y	Y	Y	New term
	Xp11 translocation RCC (C64.9)	Y	Y	Y	Y	New term
	TFEB-altered RCC (C64.9)	Y	Y	Y	Y	New term
	t(6;11) RCC (C64.9)	Y	Y	Y	Y	New term
	ELOC (formerly TCEB1) mutated RCC (C64.9)	Y	Y	Y	Y	New term
	Fumarate hydratase-deficient RCC ALK-rearranged RCC (C64.9)	Y	Y	Y	Y	New term
8361/0	Non-functioning juxtglomerular cell tumor	N	N	N	N	New code & behavior. Non-reportable
8510/3	SMARCB1-deficient medullary-like RCC (C64.9)	Y	Y	Y	Y	New term
	SMARCB1-deficient undifferentiated RCC, NOS (C64.9)	Y	Y	Y	Y	New term
	SMARCB1-deficient dedifferentiated RCC of other specific subtypes (C64.9)	Y	Y	Y	Y	New term
	Renal medullary carcinoma (C64.9)	Y	Y	Y	Y	New term
8590/0	Myoid gonadal stromal tumor	N	N	N	N	Related term. Non-reportable
8860/0	Oncocytic angiomyolipoma	N	N	N	N	New term. Not reportable
	Angiomyolipoma with epithelial cysts	N	N	N	N	New term. Not reportable
8960/1	Classic congenital mesoblastic nephroma	N	N	N	N	New term. Not reportable
	Cellular congenital mesoblastic nephroma	N	N	N	N	New term. Not reportable
	Mixed congenital mesoblastic nephroma	N	N	N	N	New term. Not reportable
8967/0	Ossifying renal tumor of infancy	N	N	N	N	New term. Not reportable
9061/2	Intratubular seminoma	Y	Y	Y	Y	New term & behavior
	Intratubular trophoblast	Y	Y	Y	Y	New term & behavior
9061/3	Seminoma with syncytiotrophoblastic cells	Y	Y	Y	Y	Related term
9063/3	Spermatocytic tumor with sarcomatous differentiation	Y	Y	Y	Y	Related term
9070/2	Intratubular embryonal carcinoma	Y	Y	Y	Y	New term & behavior
9071/2	Intratubular yolk sac tumor	Y	Y	Y	Y	New term & behavior
9080/2	Intratubular teratoma	Y	Y	Y	Y	New term & behavior
9080/3	Teratoma, postpubertal-type	Y	Y	Y	Y	New preferred term
9085/3	Mixed teratoma and yolk-sac tumor	Y	Y	Y	Y	Related term
	Diffuse embryoma	Y	Y	Y	Y	Related term
9104/3	Placental site trophoblastic tumor of testis	Y	Y	Y	Y	Behavior change from /1 to /3. Reportable for cases DX 1/1/2024 forward- Testis ONLY

(Continued on page 4)



# Florida Cancer Data System Deadlines, Updates, & Reminders

(Continued from page 3)

**Table 2: 2024 ICD-O-3.2 Update (Alpha)**

- Codes/terms listed alphabetically
- Only new terminology to existing ICD-O-3.2 codes are included in the 2024 ICD-O Implementation guidelines and documentation. Terms are those listed in WHO Blue Books
- Update based on 5<sup>th</sup> Ed Classification of Urinary and Male Genital Tumors

ICD-O Code	Term	Required SEER	Required NPCR	Required CoC	Required CCCR	Remarks
8147/3	Adenoid cystic (basal cell) carcinoma (C61.9)	Y	Y	Y	Y	Related term
8860/0	Angiomyolipoma with epithelial cysts	N	N	N	N	New term. Not reportable
8960/1	Cellular congenital mesoblastic nephroma	N	N	N	N	New term. Not reportable
8960/1	Classic congenital mesoblastic nephroma	N	N	N	N	New term. Not reportable
8120/3	Conventional urothelial carcinoma	Y	Y	Y	Y	New term
9085/3	Diffuse embryoma	Y	Y	Y	Y	Related term
8311/3	ELOC (formerly TCEB1)mutated RCC (C64.9)	Y	Y	Y	Y	New term
8311/3	Eosinophilic solid and cystic RCC (C64.9)	Y	Y	Y	Y	New term
8311/3	Fumarate hydratase-deficient RCC ALK-rearranged RCC (C64.9)	Y	Y	Y	Y	New term
9070/2	Intratubular embryonal carcinoma	Y	Y	Y	Y	New term and behavior
9061/2	Intratubular seminoma	Y	Y	Y	Y	New term and behavior
9080/2	Intratubular teratoma	Y	Y	Y	Y	New term and behavior
9061/2	Intratubular trophoblast	Y	Y	Y	Y	New term and behavior
9071/2	Intratubular yolk-sac tumor	Y	Y	Y	Y	New term and behavior
8120/3	Large nested urothelial carcinoma	Y	Y	Y	Y	New term
8130/2	Low-grade papillary urothelial carcinoma with an inverted growth pattern	Y	Y	Y	Y	New term
8960/1	Mixed congenital mesoblastic nephroma	Y	Y	Y	Y	New term. Not reportable
9085/3	Mixed teratoma and yolk-sac tumor	Y	Y	Y	Y	Related term
8590/0	Myoid gonadal stromal tumor	N	N	N	N	Related term. Not reportable
8361/1	Non-functioning juxtaglomerular cell tumor	N	N	N	N	New term and behavior. Not reportable

(Continued on page 5)



# Florida Cancer Data System Deadlines, Updates, & Reminders

(Continued from page 4)

8130/2	Non-invasive high-grade papillary urothelial carcinoma with an inverted growth pattern	Y	Y	Y	Y	New term
8130/2	Non-invasive papillary urothelial carcinoma, high-grade	Y	Y	Y	Y	New term
8130/2	Non-invasive papillary urothelial carcinoma, low-grade	Y	Y	Y	Y	New term
8860/0	<u>Oncocytic angiomyolipoma</u>	Y	Y	Y	Y	New term. Not reportable
8967/0	Ossifying renal tumor of infancy	N	N	N	N	New term. Not reportable
9104/3	Placental site trophoblastic tumor of testis	Y	Y	Y	Y	Behavior change from /1 to /3. Reportable for cases DX 1/1/2024 forward-Testis ONLY
8122/3	Plasmacytoid urothelial carcinoma	Y	Y	Y	Y	Related term
8020/3	Poorly differentiated urothelial carcinoma	Y	Y	Y	Y	Related term
8140/3	Prostatic intraepithelial-like carcinoma (C61.9)	Y	Y	Y	Y	Related term
8070/3	Pure squamous carcinoma of urothelial tract	Y	Y	Y	Y	New term
8510/3	Renal medullary carcinoma (C64.9)	Y	Y	Y	Y	New term
9061/3	Seminoma with syncytiotrophoblastic cells	Y	Y	Y	Y	Related term
8510/3	SMARCB1-deficient dedifferentiated RCC of other specific subtypes (C64.9)	Y	Y	Y	Y	New term
8510/3	SMARCB1-deficient medullary-like RCC (C64.9)	Y	Y	Y	Y	New term
8510/3	SMARCB1-deficient undifferentiated RCC, NOS (C64.9)	Y	Y	Y	Y	New term
9063/3	<u>Spermatocytic tumor with sarcomatous differentiation</u>	Y	Y	Y	Y	Related term
8085/3	Squamous cell carcinoma, HPV-associated	Y	Y	Y	Y	Valid for <u>C60.</u> ; C63.2 beginning 1/1/2024 p16 is a valid test to determine HPV status and can be used to code HPV associated and HPV independent <u>histologies</u>
8086/3	Squamous cell carcinoma, HPV-independent	Y	Y	Y	Y	Valid for <u>C60.</u> ; C63.2 beginning 1/1/2024 p16 is a valid test to determine HPV status and can be used to code HPV associated and HPV independent <u>histologies</u>
8311/3	<u>T(6;11)RCC (C64.9)</u>	Y	Y	Y	Y	New term
9080/3	Teratoma, <u>postpubertal-type</u>	Y	Y	Y	Y	New preferred term
8311/3	TFEB-altered RCC ( <b>C64.9</b> )	Y	Y	Y	Y	New term
8311/3	TFEB-rearranged RCC ( <b>C64.9</b> )	Y	Y	Y	Y	New term
8120/3	Tubular and microcystic urothelial carcinoma	Y	Y	Y	Y	New term
8260/0	<u>Tubulopapillary adenoma</u>	N	N	N	N	New term. Not reportable
8311/3	Xp11 translocation RCC ( <b>C64.9</b> )	Y	Y	Y	Y	New term



# FCDS Staff Updates

## Promotions

### **Monique Hernandez, Ph.D., Director of Administrative Operations, effective August 2023**

Dr. Hernandez has been with the FCDS for 15 years. Her current role with FCDS is Director of Administrative Operations. In the past, Dr. Hernandez has been responsible for all special projects including producing data-driven publications as well as maintaining and enhancing the web-based data visualization system. She has a multidisciplinary PhD in Epidemiology/Public Health and Geography.

### **Megsys Herna, BA, ODS-Certified, Manager, effective August 2023**

Megsys Herna joined the FCDS in August 1988. She has assumed different roles with FCDS throughout the years. Her current role as Manager oversees the daily operations of several departments: Data Acquisition, Education and Training Program, and Quality Control and Record Consolidation Systems. Megsys earned her CTR in 1995 and received her BA from the University of Miami. She was an integral part of the development and testing of the automated Tumor Consolidation Systems at FCDS. She serves on several NAACCR committees (Edits Work Group, ICD-O-3 Implementation Task Force, and the Uniform Data Standards Work Group) and serves as Co-Chair of the FCRA-FCDS Task Force.

### **Betty Malanowski, BS, IMG, ODS, Quality Control Coordinator, effective December 2023**

Betty Malanowski has been with FCDS as a Field Coordinator for our Florida reporting hospitals since 2019. She now has a new role at FCDS as a Quality Control Coordinator. Betty is a Medical Physician who graduated in 2010 in Ensenada Baja California in Mexico. She has been the Director of a Rural Medical Clinic in Mexico as well as worked in 3<sup>rd</sup> level hospitals as part of the surgical team in Open Heart surgeries and Kidney transplants. In her native country, she delivered over 300 babies and she was instrumental in treating COVID-19 patients in remote areas of Peru and Mexico during the pandemic.

## New Staff

### **Mahima Jain, MBA, Sr. Field Coordinator, effective October 2023**

Mahima Jain joined the team at FCDS in October 2023 as a Sr. Field Coordinator. She has previously worked for the Ohio Cancer Registry and brought her belief to FCDS that precise data is pivotal in shaping effective public health strategies and advancing our understanding of cancer, ultimately influencing positive outcomes for patients. She is dedicated to maintaining the highest standards of accuracy and integrity in our state's cancer registry. Her expertise and passion are vital assets to our mission and vision of enhancing healthcare quality across the hospitals we serve.

*(Continued on page 7)*

*(Continued from page 6)*

**Barbara Dearmon-Neyland, BS, ODS-Certified, Quality Control Coordinator, effective November 2023**


Barbara Dearmon-Neyland has been working in the cancer registry field since 1987. She received her BS from the University of Phoenix in healthcare services. She was previously employed by Ascension Clinical Data Science Registry services as the manager of abstraction quality. She worked in Oncology Support Services at Ascension, St. Vincent's Healthcare in Jacksonville, FL for 15 years. She has an extensive background in managing cancer registry operations, maintaining compliance with state reporting, and monitoring compliance with standards by the Commission on Cancer (CoC) and the National Accreditation Program for Breast Cancers (NAPBC). Barbara is very active at the state and national level. Barbara is a former National Cancer Registrars Association (NCRA) President, currently serves as the NCRA Education Committee chair and recipient of the NCRA 2022 Distinguished Member Award. Barbara also serves on the FCRA Board representing the FCRA Education Foundation as the secretary and on the St. John's River State College HIT Advisory Committee. Barbara likes to lead by example, share her knowledge, and mentor future oncology data specialists. Barbara has published articles in the FCRA Suntimes, the FCRA's newsletter, and NCRA publications. Barbara is proud to join the staff of FCDS.

Welcome Back

**Carlos Alvarez, OMD. BHSc. CRC. AP. BBA, Sr. Field Coordinator, effective January 2024**

Carlos Alvarez retired as a Field Coordinator from the FCDS back in October 2022. Carlos was rehired as a Sr. Field Coordinator in January 2024. He has close to 20 years of experience in the state cancer registry. One of his main roles at FCDS consists of ensuring cancer reporting compliance from private path labs, physicians, rural hospitals, radiation treatment facilities, and ambulatory surgical centers to FCDS. Carlos has a strong academic foundation holding a master's degree in Oriental Medicine and Acupuncture Physician and a bachelor's degree in health science and business administration. We are thrilled to have Carlos back.





## **The latest FCDS v23 Edits Metafile dated 11/28/2023 is on the FCDS website under Downloads**

- [ICD-10-CM Casefinding List for Reportable Tumors - Oct 1, 2023 and later encounters](#)
- [Detailed ICD-10-CM Code List for Casefinding Reportable Tumors - Oct 1, 2023 and later encounters](#)

They are to be used to identify potentially reportable tumors. Some ICD-10-CM codes contain conditions that are not reportable. These records should be reviewed and assessed individually to verify whether or not they are reportable to FCDS. ICD-10-CM implementation is expected for all hospitals nationwide on October 1, 2023. Please review **Section I of the FCDS 2023 DAM** for details on required reportable neoplasms. The FCDS 2024 DAM will be available in the Spring of 2024.

## **The latest FCDS v23 Edits Metafile dated 11/28/2023 is on the FCDS website under Downloads**

A new Florida Cancer Data System Edits Metafile was posted to the FCDS Website under the Downloads, FCDS Data Files tab. FCDS is no longer posting v23 metafiles to the NAACCR clearinghouse. Data submitted to FCDS in V23 XML must use the FCDS EDITSv23B meta-file dated 11/28/2023.





## **NAACCR Oncology Data Specialist (ODS) Exam Preparation and Review Webinar Series March 2024 Registration with FCDS is now open!**

FCDS is pleased to announce the first NAACCR ODS Exam Preparation and Review Webinar Series for 2024 offered to Florida candidates who plan to write the first ODS Exam of 2024. Florida registered participants will have full access to either/both the live and the next-day recordings of all eight 2-hour webinar sessions to view on your own time. You will also have full access to all course materials including presentations, handouts, quizzes, practice exercises, and more. In addition, you will have full access to the course instructors for Q&A. A mock ODS Exam will also be at the end of the course series to test your knowledge and skills. Webinars will be presented live every Tuesday at 2:00-4:00 pm ET. The dates of the webinars have been tentatively scheduled from February 6-March 26, 2024.

FCDS offers the NAACCR ODS Exam Preparation and Review Webinar Series at a reduced rate of \$60.00 through a special arrangement with NAACCR for 20 persons who pre-register with FCDS, meet the qualifications, and are accepted to participate by FCDS and NAACCR.

To qualify, applicants must be Florida residents, plan to write the first ODS exam of 2024, and have not taken the course before. Please Note: NAACCR and FCDS will screen all Florida Applicants to ensure they meet the criteria.

**All applicants must first register on the FCDS Pre-Registration website. Following acceptance of your pre-registration with FCDS, you will receive further instructions from Megsys Herna to complete a full registration with NAACCR and only pay the discounted rate of \$60. Registration with FCDS is now open. Click here to register [https://fcds.med.miami.edu/scripts/register\\_naaccr\\_ODS.pl](https://fcds.med.miami.edu/scripts/register_naaccr_ODS.pl).**

FCDS will track all participants' attendance if you write the ODS Exam, and if you pass or fail the exam. Individuals who take this course then take the ODS Exam that immediately follows the series but fail the examination can re-take the course next cycle **at no additional charge**.

Please contact Megsys Herna, [mherna@med.miami.edu](mailto:mherna@med.miami.edu) at FCDS for more information on the course. Please do not contact NAACCR directly to register unless you receive post-FCDS pre-registration guidance from Megsys Herna to do so or you may be charged the full price of \$235 for the course subscription.



# Remote Employment opportunities with the Florida Cancer Data System (FCDS)

The FCDS is currently the second-largest Population-based Central Cancer Registry in North America. Since 1978 the FCDS has been a joint project between NCI Sylvester Comprehensive Cancer Center at the University of Miami School of Medicine and the Florida Department of Health. The FCDS receives over 270,000 cases annually, yielding over 130,000 new incidence cases.

**The FCDS has three open positions: Two Sr. Central Cancer Registry Specialist (Sr. Field Coordinator) and one Central Cancer Registry Specialist (Field Coordinator).**

These positions are the primary contact between FCDS and our reporting sources and registrars. The responsibilities are to ensure reporting compliance from the reporting facilities, process daily cancer case submissions, review cancer data for completeness and accuracy, resolve data discrepancies following data reporting standards, and work closely with the FCDS QC team. The positions also function as the first point of contact for issues and problems for our reporting community.

## **2 - Sr. Central Cancer Registry Specialist (Sr. Field Coordinator):**

NCRA certification as a Certified Tumor Registrar (CTR) is required.

To apply <https://umiami.wd1.myworkdayjobs.com/UMCareerStaff>

Position #- R100072031

## **1- Central Cancer Registry Specialist (Field Coordinator):**

To apply <https://umiami.wd1.myworkdayjobs.com/UMCareerStaff>

Position #- R100072281

For more information, please contact Megsys Herna, at [mherna@med.miami.edu](mailto:mherna@med.miami.edu).

**2023-2024 Monthly NAACCR Cancer Surveillance Webinar Series**

FCDS is pleased to offer another year of the Monthly NAACCR Cancer Registry and Surveillance Webinar Series - Free of Charge to Florida Registrars in Recorded Sessions.

NAACCR is providing FCDS with 110 live attendance portals for 110 Florida registrars.

For registrars who do not make the short list for the live sessions, FCDS offers every NAACCR Webinar as a recorded session in FLccSC. You can still earn 3 CEUs per webinar in FLccSC. Recordings appear in FLccSC within a week or two following the live session

The 2023-2024 NAACCR Webinar Series begins on October 5, 2023 and continues through September 4, 2024. The 2023-2024 Webinar Series Schedule is provided below.

FCDS and NAACCR have an established agreement whereby any Florida FLccSC User MUST have *at least* one 'Active' User Permission or User Access Role in at least one Florida facility in IDEA to view NAACCR Webinar Recordings. All other recordings are available to any user with or without a FCDS IDEA User Role. User Roles must be updated every 6 months. FCDS recently introduced automation of access permissions that will check your individual access permission status every time you log into FLccSC regardless of how you access FLccSC (via IDEA or web). If you do not have current access to at least one facility you will not be given permission to access the NAACCR Recordings. The recordings will not even show up in your FLccSC Available Courses Menu.

<b>DATE</b>	<b>TOPIC</b>
10/5/23 9am & 2pm	<b>Lung 2023 Part 1</b> <b>Co-host: Wilson Apollo</b> Part 1 of the Lung webinar will focus on the treatment of lung cancer. We will discuss the surgery, lymph node related data items, systemic treatment, and radiation.
11/1/23 2pm 11/2/23	<b>Lung 2023 Part 2</b> <b>Co-host: Denise Harrison</b> Part 2 of the Lung webinar will focus on SSDIs and staging. Examples, quizzes, and case scenarios included.
12/7/23 9am & 2pm	<b>Radiology and Radiation (R&amp;R)</b> <b>Co-host: Wilson Apollo</b> During the webinar we will focus on imaging tools used to diagnose and stage and radiation tools used for treatment. We will discuss using information from radiology and radiation reports when
1/10/24 2pm 1/11/24	<b>Liver and Bile Ducts 2024</b> <b>Co-host: Denise Harrison</b> This webinar will cover anatomy, solid tumor rules, staging and treatment of liver and bile duct primary malignancies. Examples, quizzes, and case scenarios included.
1/31/24 2pm 2/1/24	<b>Pancreas 2024</b> <b>Co-host: Vicki Hawhee</b> This webinar will cover anatomy, solid tumor rules, staging and treatment of pancreatic primary malignancies. Examples, quizzes, and case scenarios included.
3/6/24 2pm 3/7/24 9am	<b>Boot Camp 1 2024</b> <b>Co-host: Juliet Wilkins</b> We will have 2 boot camps this year! This will allow us to spend more time on core casefinding and abstracting activities. We will spend most of our time completing and reviewing quizzes, exercises, and case scenarios. There will be minimal lecture.
4/3/24 2pm 4/4/24	<b>Boot Camp 2 2024</b> <b>Co-host: Nancy Etzold</b> We will have 2 boot camps this year! This will allow us to spend more time on core casefinding and abstracting activities. We will spend most of our time completing and reviewing quizzes, exercises, and case scenarios. There will be minimal lecture.
5/1/24 2pm 5/2/24 9am	<b>Ovary 2024</b> <b>Co-host: Connie Boone</b> This webinar will cover anatomy, solid tumor rules, staging and treatment of ovarian primary malignancies. Examples, quizzes, and case scenarios included.
6/5/24 2pm 6/6/24	<b>Thyroid 2024</b> <b>Guest Presenters: Amy Bamburg and Gillian Howell</b> This webinar will cover anatomy, solid tumor rules, staging and treatment of thyroid primary malignancies. Examples, quizzes, and case scenarios included
7/10/24 2pm 7/11/24	<b>Life in a CoC Accredited Facility in 2024</b> <b>Guest Presenters: Jennie Jones and Kim Rodriguez</b> <b>Join us for a discussion of life in a CoC accredited facility and how registrars help maintain accreditation. Kim and Jennie will discuss how they prepare for survey, quality control, RCRS, and much more!</b>
7/31/24 2pm 8/1/24	<b>CNS 2024</b> <b>Co-host: Carol Kruchko and Jennifer Ruhl</b> This webinar will cover anatomy, solid tumor rules, staging and treatment for benign and malignant primaries of the central nervous system. We will also see how the Central Brain Tumor Registry of the United States is using our data to perform research. Examples, quizzes, and case scenarios included
9/4/24 2pm 9/5/24 9am	<b>Coding Pitfalls 2024</b> <b>Co-host: Janet Vogel</b> During this webinar we will review problematic coding issues identified through quality control of registry data.

# Florida Cancer Data System

## Cancer Reporting Completeness Report



### TOTAL NUMBER OF CASES IN THE FCDS MASTER FILE AS OF DECEMBER 31, 2023

Total number of *New Cases* added to the FCDS Master file in December, 2023 12,649  
 Recurrence Abstracts Received to Date: 40,436

The figures shown below reflect initial patient encounters (admissions) for cancer by year.

ADMISSION YEAR	HOSPITAL	RADIATION	AMBI/SURG	DERMATOLOGY	PHYSICIANS CLAIMS	DCO	TOTAL CASES	NEW CASES	Tumors
2023	66,243	1,300	266	10,138	51	Pending	77,998	7,931	39,110
2022	227,605	4,487	723	13,620	14,473	Pending	260,908	3,612	139,273
2021	246,202	7,166	2,258	12,774	35,306	2,317	306,203	1,106	169,627
				<u>Actual</u>		<u>Expected</u>			<u>Expected</u>
	<b>% Complete for:</b>		<b>2023</b>	<b>31%</b>		<b>50%</b>			
			2022	100%		100%	2023		<b>30%</b>
			2021	100%		100%	2022		<b>100%</b>
							2021		<b>100%</b>

\*Expected % based on 250,000 reported cases per year

\*Tumor Expected % based on 130,000 tumors per year as of 12/14/2023 9:19:33 AM

The Florida Cancer Data System (FCDS) is Florida's statewide, population-based cancer registry and has been collecting incidence data since 1981 when it was contracted by the State of Florida Department of Health in 1978 to design and implement the registry. The University of Miami Miller School of Medicine has been maintaining FCDS (<http://fcds.med.miami.edu>) since that time.

The FCDS is wholly supported by the State of Florida Department of Health, the National Program of Cancer Registries (NPCR) of the Centers for Disease Control and Prevention (CDC) and the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.

**PROJECT DIRECTOR:**

David Lee, PhD

**DEPUTY PROJECT DIRECTOR:**

Gary M. Levin, BA, ODS

**EDITORS:**

Gary M. Levin, BA, ODS  
 Megsys C. Herna, BA, ODS-Certified  
 Melissa K. Williams

**EDITOR ASSISTANT/ GRAPHICS DESIGNER:**

Melissa K. Williams  
 Danielle Simmons

**CONTRIBUTORS:**

Megsys C. Herna, BA, ODS-Certified

## Missed an FCDS or NAACCR Webinar?



Did you know that FCDS Webcasts and NAACCR Webinars can be viewed after-the -fact?

FCDS Webcasts and NAACCR Webinars are recorded and posted on the FCDS FLccSC LMS Site.

The FCDS Webcast recordings are available free of charge and can be viewed any-time/anywhere by anybody. One must take and pass the CEU Quiz as required to obtain some of the CEUs for certain FCDS Webcasts and to obtain a Certificate of Attendance.

NAACCR Webinars are restricted to approved Florida FLccSC Users per FCDS/NAACCR agreement. NAACCR Webinars have their own CEU award mechanism whether viewed live or via a recorded session.

FCDS retains all FCDS/NAACCR recordings for 2 years in FLccSC before removing them due to outdated information.

Please contact Megsys Herna, [mherna@med.miami.edu](mailto:mhern@med.miami.edu), at FCDS for more information on viewing recorded webinars.

**FCDS**  
 PO Box 016960 (D4-11)  
 Miami, FL 33101

Phone: 305-243-4600  
 800-906-3034  
 Fax: 305-243-4871

<http://fcds.med.miami.edu>

